Welcome to Pharma Disclosure
This website has been developed as a joint initiative between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and VitalTransformation.com to highlight the industry’s new rules on disclosing financial relationships with doctors and healthcare organisations, follow progress in the implementation and to monitor compliance in the 33 countries involved in the initiative …Read more
In preparation for the implementation of The EFPIA Code outlining the disclosure of transfers of value to healthcare professionals, this webinar is an opportunity to discuss the relationship between practitioners and industry, and how improved transparency will ultimately lead to greater trust and improved patient outcomes.
Breakfast Briefing: Pharmadisclosure.EU – Promoting Greater Collaboration and Trust for Better HealthcareMay 27th 2014 - Silken Berlaymont Hotel, Brussels - 8.30-10.30
A breakfast briefing for stakeholders to showcase and outline the European Federation of Pharmaceutical Industries and Associations (EFPIA) Responsible Transparency initiative for financial and other transfers of value with healthcare professionals and organisations.
by Carin SmandTranslating the basic science of genomics into medical innovation in the form of personalised medicines requires a high level of interchange between healthcare professionals and the industry. It is critical that these relationships are based on trust and a mutual understanding, says Carin Smand, Managing Director of the European Haematology Association.
by Andrew Powrie-SmithABPI director Andrew Powrie-Smith says our responsibility to patients and society extends beyond the sale of medicines
Interview with Tim McGuire, Director, Global Health Care Professional Reporting, Eli Lilly & Company
by Tim McGuireThe voluntary disclosure of financial interactions between the pharmaceutical industry and health care professionals is another example of the continuous evolution of the pharmaceutical industry, says Tim McGuire, Director, Global Health Care Professional Reporting, Eli Lilly & Company.
by Holger DienerOver the past ten years pharmaceutical companies in Germany have proactively responded to the general trend towards greater transparency that has swept across public and corporate life. This puts the industry on the front foot in implementing the new financial disclosure code, says Dr Holger Diener, Managing Director, Association of Voluntary Self-Regulation for the Pharmaceutical Industry